Foveal LLP Independent Investment Research Foveal Research

While ASCO 2023 does not offer much in updates for the three current lead contenders for anti-TIGIT combinations in non-small cell lung canc

In newly published data from Merck /Moderna’s PD1 + mRNA cancer vaccine trial, efficacy may be flattered by Keytruda alone control arm under

As expected, TIGIT addition to PD1 failed to beat chemo in second-line patients. The failure of Merck’s TIGIT+PD1 combo to beat second line

New data from Pfizer’s pneumococcal vaccine reveals inferiority to an important serotype 3 that makes up approximately one third of cases

We examine in detail, the prospects of five near term Pfizer pipeline assets, slated for the FDA over the next 3 years and find that there a

The first factor XIa clinical efficacy for stroke prevention was presented at the European Society of cardiology in Barcelona yesterday...

We undertake a detailed analysis of seven near term Roche pipeline assets, spanning Roche’s market leading positions in Non-Hodgkin...

Roche recently announced the failure of co-primary progression free survival endpoints in both of its 1st line TIGIT trials in non-small (SK

ASCO2022 saw the eventual presentation of Pfizer's PALOMA-2 study, where, as we highlighted in our February 2020 Foveal report NOVN...

ASCO 2022 saw publication of new data for Bristol's CD-19 CAR-T Breyanzi (liso cel) in large cell non-Hodgkin’s lymphoma, along with...